|
Mutation Information
|
Mutation Site
|
M204I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
lamivudine (LAM) |
Literature Information
|
PubMed PMID
|
17178796
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2007 |
|
Journal
|
Antimicrobial agents and chemotherapy |
|
Title
|
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. |
|
Author
|
Tenney DJ,Rose RE,Baldick CJ,Levine SM,Pokornowski KA,Walsh AW,Fang J,Yu CF,Zhang S,Mazzucco CE,Eggers B,Hsu M,Plym MJ,Poundstone P,Yang J,Colonno RJ |
|
Evidence
|
At study entry, 85% (397/466) of the patients enrolled in the 1.0-mg ETV and 100-mg LVD arms of studies 014, 015, and 026 had the primary LVDr-encoding substitution M204I or the substitution M204V with or without the L180M substitution, detectable by nucleotide sequencing of the RT gene within population quasispecies.
|
|
|
HBV Mutation Detail Information